KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Long-Term Investments (2016 - 2026)

Gsk has reported Long-Term Investments over the past 18 years, most recently at $1.2 billion for Q1 2026.

  • For Q1 2026, Long-Term Investments fell 1.45% year-over-year to $1.2 billion; the TTM value through Mar 2026 reached $1.2 billion, down 1.45%, while the annual FY2025 figure was $1.4 billion, 1019.48% up from the prior year.
  • Long-Term Investments for Q1 2026 was $1.2 billion at Gsk, down from $1.4 billion in the prior quarter.
  • Over five years, Long-Term Investments peaked at $2.2 billion in Q1 2022 and troughed at -$1.2 million in Q3 2022.
  • A 5-year average of $1.2 billion and a median of $1.4 billion in 2023 define the central range for Long-Term Investments.
  • On a YoY basis, Long-Term Investments climbed as much as 114779.45% in 2023 and fell as far as 96.03% in 2023.
  • Year by year, Long-Term Investments stood at $1.7 billion in 2022, then plummeted by 96.03% to $68.3 million in 2023, then soared by 80.5% to $123.2 million in 2024, then soared by 1019.48% to $1.4 billion in 2025, then dropped by 16.04% to $1.2 billion in 2026.
  • Business Quant data shows Long-Term Investments for GSK at $1.2 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.3 billion in Q3 2025.